Possible Role of Organic Cation Transporters in the Distribution of [11 C]Sulpiride, a Dopamine D2 Receptor Antagonist

Journal of Pharmaceutical Sciences
Harumasa TakanoYuichi Sugiyama

Abstract

We synthesized [11C]sulpiride as a positron emission tomography probe for investigating the drug distribution in the human body. [11C]Sulpiride was injected to healthy male subjects in either tracer dose of [11C]sulpiride (approximately 222 MBq) or with therapeutic dose of sulpiride (500 mg, peroral) 3 h before the injection in a crossover fashion. Whole-body positron emission tomography imaging demonstrated that [11C]sulpiride accumulated exceedingly in the bladder, followed by liver, gall bladder, and kidney, respectively, at 30 min after the injection, whereas scarcely in the brain. Oral dose of sulpiride decreased the hepatic accumulation of the radioactivity by 60%. From in vitro experiments, we found that sulpiride is a substrate of hOCT1 (Km 2.6 μM), hOCT2 (Km 68 μM), hMATE1 (Km 40 μM), and hMATE2-K (Km 60 μM). Moreover, the uptake of sulpiride by human hepatocytes was diminished by tetraethylammonium, and saturable with Km of 18 μM. Oct1/2 double knockout mice and wild-type mice received Mate1 inhibitors (pyrimethamine/cimetidine) manifested reduced renal clearance of sulpiride, accompanied with its accumulation in the plasma. In conclusion, we found that sulpiride is a substrate of OCT1, OCT2, MATE1, and MATE2-K, and t...Continue Reading

References

Aug 1, 1984·Journal of Pharmaceutical Sciences·F BressolleR Gomeni
Nov 1, 1981·Journal of Pharmacobio-dynamics·K YamaokaT Uno
May 1, 1980·European Journal of Clinical Pharmacology·F A WieselG Sedvall
May 26, 2004·The Journal of Pharmacology and Experimental Therapeutics·Masaru HiranoYuichi Sugiyama
Nov 3, 2005·Biochemical Pharmacology·Johanna MüllerMatthias Brandsch
Nov 18, 2005·The International Journal of Neuropsychopharmacology·Akihiro TakanoYoshiro Okubo
Dec 17, 2008·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Soichiro MatsushimaYuichi Sugiyama
Jan 13, 2010·The Journal of Pharmacology and Experimental Therapeutics·Sumito ItoYuichi Sugiyama
Aug 16, 2011·British Journal of Clinical Pharmacology·Paul M MatthewsRoger N Gunn
Apr 14, 2012·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Tadayuki TakashimaYasuyoshi Watanabe
Feb 26, 2013·The AAPS Journal·Hideyuki Motohashi, Ken-ichi Inui
Apr 26, 2013·Clinical Pharmacology and Therapeutics·H Kusuhara
Jul 25, 2015·Expert Opinion on Drug Metabolism & Toxicology·Hermann Koepsell
Jun 19, 2016·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·David J WagnerJoanne Wang
Jul 30, 2016·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Lars C GormsenNiels Jessen

❮ Previous
Next ❯

Citations

Sep 20, 2017·Biopharmaceutics & Drug Disposition·Liping LiHuidi Jiang
Jul 31, 2018·Clinical Pharmacology and Therapeutics·Yingying GuoUNKNOWN International Transporter Consortium
Jan 18, 2020·Expert Opinion on Drug Metabolism & Toxicology·Irene Hernández Lozano, Oliver Langer
Mar 12, 2019·Drug Metabolism Letters·Liyue HuangZhiyang Zhao
Dec 20, 2019·Pharmacological Reviews·Hermann Koepsell
Mar 9, 2021·Frontiers in Pharmacology·Shiwei ZhouYan Shu
May 4, 2021·Frontiers in Pharmacology·Christoph WenzelStefan Oswald

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.